 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Apr 10, 2008 |
| Title |
Molecular Classification and Prediction of Survival in Non-Small-Cell Lung Cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
BACKGROUND: Global gene expression analysis provides a comprehensive molecular characterization of non-small cell lung cancer. The aim of this study was to evaluate the feasibility of integrating expression profiling into routine clinical work-up by including minute bronchoscopic biopsies and develop a robust prognostic gene expression signature
METHODS: Tissue samples from a series of 41 chemotherapy-naïve non-small cell lung cancer patients and 15 control patients with inflammatory lung diseases were obtained during routine clinical work-up and gene expression profiles were gained using a highly sensitive oligonucleotide array platform (Novachip ; 34'207 transcripts). Gene expression signatures were analyzed by correlation with histological and clinical parameters and validated on independent published datasets and immunohistochemistry.
RESULTS: Tumor tissue classification based on the gene expression results was strongly dependent on the proportion of tumor cells present in the biopsies and showed an overall sensitivity of 80% and specificity of 89%. For prognostication we developed a metagene consisting of 13 genes, which was validated on 4 independent published datasets. The robustness of this metagene has been demonstrated by a virtual independence from tumor cells present in the biopsies. Furthermore, vascular endothelial growth factor-beta, one of the key prognostic genes was validated by immunohistochemistry on 508 independent tumor samples.
CONCLUSIONS: The proposed strategy of integrating functional genomics into routine clinical work-up allows molecular tumor classification and prediction of survival in patients with non-small cell lung cancer of all stages and is suitable for an integration in the daily clinical practice.
Keywords: Gene expression profiling for disease state analysis in lung cancer patients
|
| |
|
| Overall design |
56 lung biopsies, 4 different Phenotypes: NSCLC-squa., NSCLC-NOS, NSCLC-Adeno, Ctr.-Infl.
|
| |
|
| Contributor(s) |
Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche MH |
| Citation(s) |
19833826 |
| |
| Submission date |
Apr 09, 2008 |
| Last update date |
Mar 19, 2012 |
| Contact name |
Wolfgang Ernst Gustav Budach |
| E-mail(s) |
[email protected]
|
| Phone |
+41 61 6961391
|
| Fax |
+41 61 6966212
|
| Organization name |
Novartis Pharma AG
|
| Department |
BMD/NV&D
|
| Lab |
WKL-136.293
|
| Street address |
Klybeckstrasse
|
| City |
Basel |
| ZIP/Postal code |
4002 |
| Country |
Switzerland |
| |
|
| Platforms (1) |
|
| Samples (56)
|
|
| Relations |
| BioProject |
PRJNA107013 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE11117_RAW.tar |
32.7 Mb |
(http)(custom) |
TAR (of TXT) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...